The city of Grand Rapids, Michigan, currently has 3 active clinical trials seeking participants for Epilepsy research studies.
Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age with Partial-onset (focal) Seizures
Recruiting
Primary objective: To evaluate the safety and tolerability of cenobamate in pediatric subjects 2-17 years of age with partial-onset (focal) seizures
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
12/16/2024
Locations: Spectrum Health Hospitals Helen DeVos Children's Hospital, Grand Rapids, Michigan
Conditions: Partial Epilepsy
AMT-260 Gene Therapy Study in Adults with Unilateral Refractory Mesial Temporal Lobe Epilepsy
Recruiting
This is a study of AMT-260 in Adults with Unilateral Refractory Mesial Temporal Lobe Epilepsy (MTLE). It is designed to investigate the Safety, Tolerability, and Efficacy of AMT-260 in Adults with MTLE Administered via Magnetic Resonance Imaging (MRI)-guided Convection-enhanced Delivery (CED).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
11/27/2024
Locations: Corewell Health, Grand Rapids, Michigan
Conditions: Mesial Temporal Lobe Epilepsy
RNS System RESPONSE Study
Recruiting
To demonstrate that the RNS System is safe and effective as an adjunctive therapy in individuals age 12 through 17 years with medically refractory partial onset epilepsy.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
11/12/2024
Locations: Spectrum Health System, Grand Rapids, Michigan
Conditions: Epilepsy, Partial Seizure, Neurostimulator; Complications, Drug Resistant Epilepsy, Focal Epilepsy